SITC年会则是专注于肿瘤免疫治疗,为全球数千名学术界、监管机构的行业领袖提供了一个多学科交流的平台,致力共同推动科学进步,发现突破性的进展,改善癌症患者的预后。 IVC2024会议邀请上海细胞治疗集团新药创制BG总裁刘颐博士进行口头报告 SITC会议收录纳米抗体装甲化DC肿瘤疫苗的最新研究进展(poster展示,摘要号:1041) 以下...
New for SITC 2024 - Call for Immune Engineering Abstracts This year the Pre-Conference Program, Immune Engineering Workshop, on Thursday, Nov. 7, from 9 a.m.–5 p.m., will offer additional opportunities for poster and oral presentations. Abstracts that focus on immune engineering and related...
BeyondSpring Inc. announced the presentation of a poster at the Society for Immunotherapy of Cancer's 38th Annual Meeting, taking place on November 3 through 5 in San Diego, CA.
and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the Society for
Through its participation at SITC and poster presentations, GC Cell aims to showcase its technological prowess and competitiveness on the global stage while establishing strategic networks for potential collaborations and partnerships.tweet Related articlesGC...
Y-Biologics has secured two poster presentations, including research on AR148, a solid cancer that applies its TGFβ SelecTrap technology. The company's AR148, designed through AI modeling, selectively inhibits TGFβ 1 and 3 with lower toxicity than existing treatments. They will also present fi...
SITC 2024 abstract Data cut off: May 16, 2024 Note: The poster to be presented at SITC on November 8, 2024 will include additional data Treatment COM701+COM902+pembrolizumab No. patients 23 (efficacy evaluable) Confirmed ORR 17.4% (1 CR, 3 PR) Confirmed DCR 43.5 % ...
SITC 2024 Poster Presentation Title:Multi-antigen Targeting with CAR and TCR Co-expression in Allogeneic Cell Therapy for Solid Tumors Presenting Author:Sergio M. Quinones-Parra, Ph.D., Poseida Therapeutics Presentation Date/Time:Saturday, ...
Poster Presentation Details: Title: CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC) Abstract Number: 1397 Presentation Date: Friday, November ...
The poster presentation, entitled "Phase 1/2a Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2) as Single Agent and in Combination with Pembrolizumab"include data from the BI-1808 monotherapy arm of the Phase 1 study and display...